Fourth quarter 2022 adjusted earnings per diluted share is expected to be above the high end of the Company’s October guidance range.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on IART:
- Integra LifeSciences Reports Select Preliminary Fourth Quarter and Full-Year 2022 Financials
- Integra LifeSciences to Present at 41st Annual J.P. Morgan Healthcare Conference
- Integra LifeSciences price target raised to $60 from $50 at Citi
- Integra LifeSciences Completes the Acquisition of Surgical Innovation Associates
- Integra LifeSciences plans $150M share repurchase